Abstract:Key Points Macrophage-stimulating protein (MSP; also known as MST1 and hepatocye growth factor-like (HGFL)), is a serum-derived growth factor that activates the RON receptor tyrosine kinase. RON signalling is essential for the survival of embryos during the peri-implantation period. Cancer cells use MSP–RON signalling for survival, migration, angiogenesis and chemoresistance, which has pathogenic implications. Crystal structure analyses have shown that a central cleft harbouring three amino acid residues in the putative catalytic site of the MSP β-chain interacts with an interface created by two RON semaphorin (SEMA) domains. This supports a model in which one MSP molecule binds two RON molecules to cause receptor dimerization and activation. Aberrant RON activation, which is induced by overexpression of protein and the generation of oncogenic isoforms and is indicated by the persistent activation of multi-intracellular signalling cascades, occurs in various types of cancers. RON signalling is also necessary for cancer cell growth and survival. These features render RON as a drug target for cancer therapy. MSP–RON signalling activates two classical signalling pathways, RAS–ERK and PI3K–AKT, both of which interact with various other pathways to create a complex signalling network. RON also crosstalks with other receptor tyrosine kinases and viral oncoproteins. Such intricate interactions highlight the importance of RON signalling in cancer pathogenesis. Overexpression of RON in primary tumours such as colon and breast cancer is predictive of patient survival and correlates with clinical and pathological parameters. Studies from mouse xenograft models have revealed that inhibition of RON by tyrosine kinase inhibitors and monoclonal antibodies blocks tumour growth. However, combinations with chemoagents achieve maximum therapeutic benefit. The tyrosine kinase inhibitor BMS-777607 and the RON-specific antibody narnatumab are currently in Phase I clinical trials.

Collaborative Activities of Macrophage-Stimulating Protein and Transforming Growth Factor- Β 1 in Induction of Epithelial to Mesenchymal Transition: Roles of the RON Receptor Tyrosine Kinase

Ribosomal Protein S6 Kinase (RSK)-2 As a Central Effector Molecule in RON Receptor Tyrosine Kinase Mediated Epithelial to Mesenchymal Transition Induced by Macrophage-Stimulating Protein

Mechanisms of RON-mediated Epithelial-Mesenchymal Transition in MDCK Cells Through the MAPK Pathway

Alterations in a Defined Extracellular Region of the RON Receptor Tyrosine Kinase Promote RON-mediated Motile and Invasive Phenotypes in Epithelial Cells.

Oncogenesis of RON Receptor Tyrosine Kinase： a Molecular Target for Malignant Epithelial Cancers

RON Mediates Tumor-Promoting Effects in Endometrial Adenocarcinoma

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

Effects of Heterogously- Expressed RON Receptor Tyrosine Kinase on Motile/invasive Ability of Human Colorectal Cancer Cell Line RKO

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential

Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo

Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells

Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines.

Receptor tyrosine kinase RON and tumor

MSP–RON signalling in cancer: pathogenesis and therapeutic potential

Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.

Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

β-Arrestin-1-dependent activation of extracellular signal-regulated kinases in RON receptor-mediated tumorigenic activities in colon cancer cells

Inhibition of MSP-RON Signaling Pathway in Cancer Cells by a Novel Soluble Form of RON Comprising the Entire Sema Sequence.

Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.

Agonistic Monoclonal Antibodies Potentiate Tumorigenic and Invasive Activities of Splicing Variant of the RON Receptor Tyrosine Kinase